JCAR018
/ BMS, National Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 17
Of
17
Go to page
1
November 04, 2024
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1 | N=133 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jun 2040 ➔ Oct 2024
Trial completion • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22
January 19, 2024
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1 | N=123 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting
Enrollment closed • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22
November 07, 2023
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1 | N=123 | Suspended | Sponsor: National Cancer Institute (NCI) | N=208 ➔ 123 | Recruiting ➔ Suspended
Enrollment change • Trial suspension • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22
May 12, 2022
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
(clinicaltrials.gov)
- P1 | N=23 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting
Enrollment open • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22
May 17, 2021
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=208; Recruiting; Sponsor: National Cancer Institute (NCI); N=126 ➔ 208
Clinical • Enrollment change • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
August 31, 2020
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=126; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2035 ➔ Jun 2040; Trial primary completion date: Jun 2022 ➔ Jun 2025
Clinical • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
November 07, 2017
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=31; Suspended; Sponsor: National Cancer Institute (NCI); N=115 ➔ 31; Recruiting ➔ Suspended
Clinical • Enrollment change • Trial suspension • Follicular Lymphoma • Pediatrics • CD22 • PCR
June 08, 2017
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=115; Recruiting; Sponsor: National Cancer Institute (NCI); N=67 ➔ 115; Trial primary completion date: Jun 2017 ➔ Jun 2018
Clinical • Enrollment change • Trial primary completion date • Follicular Lymphoma • Pediatrics • CD22 • PCR
August 09, 2016
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=57; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Jan 2017 ➔ Jan 2018
Clinical • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
June 12, 2017
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=115; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Jun 2018 ➔ Jun 2019
Clinical • Trial primary completion date • Follicular Lymphoma • Pediatrics • CD22 • PCR
January 10, 2017
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=57; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Jan 2018 ➔ Jun 2017
Clinical • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
June 17, 2020
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=126; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Jun 2020 ➔ Jun 2022
Clinical • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
December 13, 2014
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=57; Recruiting; Sponsor: National Cancer Institute (NCI)
Clinical • New P1 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
March 25, 2021
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
(clinicaltrials.gov)
- P1; N=23; Not yet recruiting; Sponsor: National Cancer Institute (NCI)
Clinical • IO biomarker • New P1 trial • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22
April 20, 2019
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=110; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2020 ➔ Jun 2035; Trial primary completion date: Jun 2019 ➔ Jun 2020
Clinical • Trial completion date • Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
November 18, 2017
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
(clinicaltrials.gov)
- P1; N=115; Recruiting; Sponsor: National Cancer Institute (NCI); Suspended ➔ Recruiting; N=31 ➔ 115
Clinical • Enrollment change • Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • CD22 • PCR
June 12, 2017
"Muy interesante, $JUNO increased CD22 CART enrollment, while PENN terminates their CD22 CAR-T trial $NVS $KITE https://t.co/SRK3Zk2Re9"
(@DrPaulyDeSantis)
Biosimilar
1 to 17
Of
17
Go to page
1